At FMI, we maintain a fixed analytical framework structured as Product × Technology × Application × Channel × Region, covering seven global regions and thirty countries. Units for value and volume, along with the currency basis, are defined at the outset to keep all measurement consistent throughout the workflow. Monthly indicators shape our quarterly baselines, allowing early shifts to be captured before formal reporting cycles close. Forecasts operate at constant FX unless scenario requirements dictate an alternate treatment. Segment trees are finalized before data ingestion, and any structural revision passes through formal change control so that continuity and auditability remain intact.
We measure shipments at the point of vendor-to-channel dispatch, ensuring that each unit is counted once. OEM transfers are excluded from double attribution because the finished product brand receives full credit. Subsidiary stock enters measurement only once it reaches the channel. Known re-export routes are reassigned to the country of final usage when this can be reliably determined. Our installed base tracking incorporates manufacturer self-consumption and documented donation programs to maintain an accurate device count in use.
ASP is captured at the distributor level with freight, insurance, and import duties included within vendor or channel pricing, while point-of-sale taxes remain outside the scope. Outliers are normalized. Our pricing weights combine international, domestic, and China-based vendors according to each geography and application mix. Bulk chemicals and intermediates follow bulk distributor pricing structures.
Value is calculated as Units multiplied by ASP. Installed base equals cumulative shipments minus retirements derived from survival curves calibrated by device class. Apparent capacity is generated from production, net trade, and a capacity factor that generally falls between 80 and 90 percent under typical operating day and hour configurations. Historical data is expressed in current-period USD, and forward values are held at constant FX unless scenario work specifies another treatment.
Brand share is calculated as Brand Value divided by Category Value for each defined geography and channel. When EPOS data is unavailable, we triangulate brand value from filings, tender outcomes, distributor catalogs, and multi-signal proxies such as SRAP, PII, and RHI. Corridor tests bound feasible ranges using capacity and shipment signals for minimum values and price-volume logic for maximum values.
We compile trade flows using HS codes and reinforce them with mirror statistics to identify gaps or inconsistencies. Adjustments account for re-exports through transit hubs, valuation differences between FOB and CIF, and reclassification events that may distort time series. All data is time-aligned and currency-normalized. Apparent consumption is closed using the formula Production + Imports − Exports, with adjustments for stock variation when stock signals are observable.
Our channel analysis allocates revenue and volume across direct, distributor or wholesale, retail or mass, pharmacy or specialty, e-commerce, and tender or government pathways depending on the structure of each category. Margin stacks are modeled for every channel. Leakage arising from grey or parallel trade is estimated using guardrails informed by pricing patterns, stock anomalies, and availability inconsistencies. Attach-rate models quantify linked consumables and service components when category behavior supports such linkages.
We map supply chains end-to-end, covering capacity, utilization, cycle time, yield, scrap, lead time, lane reliability, and inventory policies. Supplier and buyer concentration metrics flag structural exposures. We stress-test single-point vulnerabilities under demand and supply shocks to understand plausible system behavior. Supplier scorecards track quality, delivery performance, cost variance, and emerging risk signals, enabling a fact-based view of supply stability.
Our first forecasting method uses regression-based structures with predictors drawn from production, utilization patterns, trade flows, capital expenditure, orders and backlog, pricing corridors, regulatory approvals, standards, and policy variables. Transformations are applied only when they improve out-of-sample performance. We run stability checks, break tests, backtests, and diagnostic reviews before a model is retained.
Our second forecasting method applies driver growth-rate structures to the most recent audited baseline, used when data is sparse or volatile. Weights are tuned to realized outcomes without overfitting and are updated when drivers rebase or shocks occur. Triangulation incorporates Product Category Analysis, n-per-Population intensity checks, and an Economic Envelope that ensures forecast feasibility under macro and budget constraints. Output includes value, volume, installed base, and price scenarios supported by confidence intervals.
We monitor regression accuracy using MAPE alongside residual diagnostics and stability tests. Growth-rate structures are validated through correlation checks and backtests against historical vintages with tolerance bands set according to category volatility. Reconciliation ensures closure of apparent consumption, and price corridors, capacity constraints, and FX limits are assessed. Every dataset and model receives a second-analyst review, and all changes are recorded with clear rationale through maintained change logs.
At FMI, we monitor a structured set of industry specific signals that strengthen the accuracy and credibility of our medical device analyses. We track these indicators because device performance is shaped by regulatory processes, clinical behavior, operational constraints, and provider purchasing patterns, and each dimension contributes evidence that supports our baselines and forecasts. Our approach ensures that every data series is grounded in verifiable activity rather than heuristic assumptions.
Our tracked signals span regulatory, clinical, operational, and commercial domains. Regulatory signals include approvals, clearances, notified body certifications, technical file updates, vigilance notices, and field action summaries, which help us anticipate launch timing, compliance actions, and risk implications. Clinical signals include trial initiations, completions, endpoint outcomes, complication patterns, revisions, and guideline updates. These metrics inform adoption curves, replacement intervals, and real world usage intensity across care settings.
Operational signals cover manufacturing throughput, sterilization capacity, packaging readiness, supplier lead times, backlog formation, tender cycles, and replacement rhythms for provider owned assets. Utilization signals incorporate procedure volumes, scan counts, occupancy ratios, and shifts in case mix across hospitals, ambulatory centers, and specialized clinics. Commercial signals include distributor load in patterns, channel pricing, reimbursement updates, formulary decisions, and procurement frameworks that influence volume pacing and substitution effects.
Each signal is validated through triangulation with practitioner interviews, hospital standard operating practices, supply chain checkpoints, regulatory filings, and technical documentation. When information is sparse, we rely on documented clinical pathways or regulatory requirements to maintain methodological discipline and prevent misinterpretation. This multi signal structure stabilizes our forecasts in categories where treatment protocols evolve or procurement behavior introduces variability.
Value = Units × ASP; Installed Base = Σ Shipments − Retirements; Apparent Capacity = Production / Capacity Factor; Brand Share = Brand Value ÷ Category Value; Channel Mix = Channel Revenue ÷ Total; Export–Import Balance = Exports − Imports.
UN Comtrade/ITC Trade Map; Eurostat/PRODCOM; US Census/BEA/BLS; OECD; IEA/EIA/USGS/UNCTADstat; FAOSTAT/USDA; FDA/EMA/PMDA/CDSCO; ClinicalTrials.gov/WHO ICTRP; OICA/ACEA/SIAM; EDGAR/SEMI/GSMA/3GPP; EU TED/SAM.gov; public retail signals (filings, store locators, circulars, app stores, public social). Lineage cards display pull dates, access type, transforms, confidence tier, and caveats.
Quarterly baselines with monthly micro-updates for high-frequency shifts; rapid shock notes for policy/outage/recall/price spikes. Deliverables include executive memo, workbook/models, 16:9 dashboards with lineage, and a change log. Optional: weekly SRAP/PII/RHI tiles for retail.
Methodology
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
